Breaking News Instant updates and real-time market news.

YOGA

YogaWorks

$4.00

-0.04 (-0.99%)

, TXN

Texas Instruments

$86.05

0.22 (0.26%)

18:11
09/21/17
09/21
18:11
09/21/17
18:11

On The Fly: After Hours Movers

UP AFTER EARNINGS: Yogaworks (YOGA), up 1.25% after reporting Q2 results and giving Q3 guidance. ALSO HIGHER: Texas Instruments (TXN), up 0.8% after raising its dividend 24% and adding to its stock repurchase program. DOWN AFTER EARNINGS: Presidio (PSDO), down 6.8% after reporting Q4 results. ALSO LOWER: Versartis (VSAR), down 83.3% after its Phase 3 of somavaratan did not meet its primary endpoint. Note that shares of competitor Ascendis Pharma (ASND) spiked higher by 44% after the news.

YOGA

YogaWorks

$4.00

-0.04 (-0.99%)

TXN

Texas Instruments

$86.05

0.22 (0.26%)

PSDO

Presidio

$13.95

-0.06 (-0.43%)

VSAR

Versartis

$21.60

-0.25 (-1.14%)

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

  • 21

    Sep

  • 21

    Sep

YOGA YogaWorks
$4.00

-0.04 (-0.99%)

09/05/17
09/05/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Owens-Illinois (OI) initiated with a Neutral at UBS. 2. Akamai (AKAM) initiated with a Neutral at Credit Suisse. 3. Zealand Pharma (ZEAL) was initiated with a Buy at Needham and Guggenheim while being initiated with an Overweight at Morgan Stanley. 4. YogaWorks (YOGA) was initiated with an Outperform at Cowen, an Overweight at Stephens, and a Buy at Roth Capital and Guggenheim. 5. Red Hat (RHT) initiated with a Neutral at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/05/17
SPHN
09/05/17
INITIATION
Target $6
SPHN
Overweight
YogaWorks initiated with an Overweight at Stephens
Stephens analyst Ben Bienvenu started YogaWorks with an Overweight rating and $6 price target.
09/05/17
COWN
09/05/17
INITIATION
Target $7
COWN
Outperform
YogaWorks initiated with an Outperform at Cowen
Cowen analyst Oliver Chen initiated YogaWorks with an Outperform and a $7 price target highlighting 25%+ growth and potential market share gains.
09/05/17
ROTH
09/05/17
INITIATION
Target $7
ROTH
Buy
YogaWorks initiated with a Buy at Roth Capital
Roth Capital analyst Dave King started YogaWorks with a Buy rating and $7 price target, as he sees the company being poised to continue capitalizing on growth in yoga participation and cites its expertise in consolidating the highly-fragmented studio market.
TXN Texas Instruments
$86.05

0.22 (0.26%)

07/24/17
RBCM
07/24/17
NO CHANGE
RBCM
Texas Instruments June results poised to beat expectations, says RBC Capital
RBC Capital analyst Amit Daryanani, predicts that Texas Instruments' June quarter results will beat expectations, while its September quarter guidance range will include the consensus outlook. The analyst says that the company's "revenue backdrop" was "favorable" last quarter, and he thinks that Analog demand continues to be "robust." He keeps a $95 price target and an Outperform rating on the stock.
09/13/17
FBCO
09/13/17
NO CHANGE
FBCO
Apple launch mostly as expected, says Credit Suisse
Credit Suisse analyst John Pitzer notes that Apple (AAPL) has announced four product updates largely in-line with expectations, and points out that semi companies in his coverage universe with exposure to Apple include Broadcom (AVGO), Micron (MU) and Texas Instruments (TXN).
09/21/17
BMOC
09/21/17
NO CHANGE
BMOC
Texas Instruments price target raised to $105 from $92 at BMO Capital
BMO Capital analyst Ambrish Srivastava thinks that Texas Instruments' EPS will reach $5.79 over the longer term, while its free cash flow per share will reach $6.47. The analyst says that the company would benefit more from tax reform than any other name he covers, due to its tax structure. He raised his price target on the stock and keeps an Outperform rating on the shares.
07/26/17
SBSH
07/26/17
NO CHANGE
Target $97
SBSH
Buy
Texas Instruments price target raised to $97 from $87 at Citi
Citi analyst Christopher Danely raised his price target for Texas Instruments to $97 saying the company reported strong Q2 results and guided above expectations "due to broad-based strength." He believes Texas Instruments has one of the highest total returns in Citi's coverage universe. The analyst keeps a Buy rating on the shares.
PSDO Presidio
$13.95

-0.06 (-0.43%)

04/04/17
JPMS
04/04/17
INITIATION
Target $18
JPMS
Overweight
Presidio initiated with an Overweight at JPMorgan
JPMorgan analyst Tien-tsin Huang started Presidio with an Overweight rating and $18 price target. The analyst says the company is "in the "right markets with the right solutions at the right time."
04/04/17
WELS
04/04/17
INITIATION
WELS
Outperform
Presidio initiated with an Outperform at Wells Fargo
Wells Fargo analyst Ed Caso started Presidio with an Outperform rating and $17-$18 price target range. The analyst believes the company is "addressing the increasingly critical needs of digital technology in an under-served market space."
04/04/17
RBCM
04/04/17
INITIATION
Target $19
RBCM
Outperform
Presidio initiated with an Outperform at RBC Capital
RBC Capital analyst Amit Daryanani with an Outperform and a $19 price target given solid free cash flow generation, ability for revenue growth to outpace broader IT spending, and low to mid-teens earnings growth potential driven by mix shift to higher margin revenue.
04/04/17
FBCO
04/04/17
INITIATION
Target $18
FBCO
Outperform
Presidio initiated with an Outperform at Credit Suisse
Credit Suisse analyst Kulbinder Garcha started Presidio with an Outperform rating and a $18 price target as he believes the company has a niche in the secular growth of the middle-market IT segment with a positive mix-shift toward services.
VSAR Versartis
$21.60

-0.25 (-1.14%)

09/01/17
LEER
09/01/17
NO CHANGE
Target $28
LEER
Market Perform
Ascendis shares could move 20% on Versartis data, says Leerink
Leerink analyst Joseph Schwartz believes shares of Ascendis Pharma (ASND) could move up or down 20% on Versartis' (VSAR) somavaratan data in September. The data may have important read-through for Ascendis since it may indicate how much of the long-acting growth hormone market TransCon hGH will need to compete for. The analyst notes his base case scenario has Ascendis shares remaining flat or trading slightly down on somavaratan efficacy, which is "noninferior to daily Genotropin and safety which is acceptable." Schwartz reiterates a Market Perform rating on Ascendis with a $28 price target.
06/27/17
PIPR
06/27/17
NO CHANGE
Target $26
PIPR
Overweight
Piper a buyer of Versartis ahead of September data
Piper Jaffray analyst Edward Tenthoff says he's a buyer of Versartis shares ahead of the Phase III Velocity data on somavartan in pediatric growth hormone deficiency expected in September. The analyst is "confident" somavaratan will meet the primary endpoint of non-inferior height velocity at 12 months based on Phase II Vista data that showed consistent HV out to three years. He reiterates an Overweight rating on the shares with a $26 price target.
05/05/17
05/05/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Snap (SNAP) initiated with a Buy at Cleveland Research. 2. Versartis (VSAR) initiated with an Overweight at Cantor. 3. Alder Biopharmaceuticals (ALDR) initiated with a Sell at UBS. 4. Playa Hotels & Resorts (PLYA) initiated with a Neutral at Citi. 5. Coherus Biosciences (CHRS) initiated with an Outperform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/08/17
PIPR
09/08/17
NO CHANGE
Target $26
PIPR
Overweight
Piper says own Versartis into Phase III data later this month
Piper Jaffray analyst Edward Tenthoff recommends owning shares of Versartis into the Phase III Velocity data on somavaratan in pediatric growth hormone deficiency due by the end of September. The analyst continues to expect somavaratan to demonstrate non-inferior height velocity within the 2cm lower confidence interval to daily growth hormone at one year. Even if somavaratan produces numerically lower height velocity to daily growth hormone, this would be a win since less frequent dosing should result in higher real-world compliance and growth, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Versartis with a $26 price target.
ASND Ascendis Pharma
$27.74

-1.55 (-5.29%)

05/11/17
05/11/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Methanex (MEOH) initiated with an Underperform at Bernstein. 2. PTC (PTC) initiated with an Outperform at Baird. 3. Pioneer Natural (PXD) assumed with an Overweight at Piper Jaffray. 4. Ascendis Pharma (ASND) initiated with an Overweight at JPMorgan. 5. Control4 (CTRL) initiated with a Hold at Maxim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/11/17
JPMS
05/11/17
INITIATION
Target $36
JPMS
Overweight
Ascendis Pharma initiated with an Overweight at JPMorgan
JPMorgan analyst Jessica Fye started Ascendis Pharma with an Overweight rating and $36 price target. The TransCon platform provides a "de-risked approach to developing long-acting therapeutics," the analyst writes.
03/09/17
LEER
03/09/17
DOWNGRADE
Target $30
LEER
Market Perform
Ascendis Pharma downgraded to Market Perform from Outperform at Leerink
Leerink analyst Joseph Schwartz downgraded Ascendis Pharma to Market Perform from Outperform saying the stock's growth spurt looks excessive given limited near-term catalysts. While the analyst continues to expect market entry in 2020 for the lead product, TransCon hGH, and incremental updates for the company's pre-clinical pipeline programs through 2017, he does not see strong reasons for such exuberance to continue over the near-term. Schwartz raised his price target on the shares to $30 from $24.

TODAY'S FREE FLY STORIES

WILC

G. Willi-Food

$5.85

-0.14 (-2.34%)

18:35
10/19/17
10/19
18:35
10/19/17
18:35
Hot Stocks
G. Willi-Food receives notice from Arla Food ending distribution agreement »

G. Willi-Food's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MIC

Macquarie Infrastructure

$71.26

-0.46 (-0.64%)

18:30
10/19/17
10/19
18:30
10/19/17
18:30
Hot Stocks
Macquarie Infrastructure CEO to become CEO of Macquarie Atlas Roads in 2018 »

Macquarie Infrastructure…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

BIDU

Baidu

$264.52

-4.45 (-1.65%)

18:30
10/19/17
10/19
18:30
10/19/17
18:30
Hot Stocks
Baidu collaborating with China's BAIC Group and King Long for autonomous driving »

Baidu signed strategic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

IBKC

Iberiabank

$80.15

0.05 (0.06%)

18:27
10/19/17
10/19
18:27
10/19/17
18:27
Hot Stocks
IBERIABANK to acquire Gibraltar Private Bank & Trust »

IBERIABANK Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 15

    Nov

  • 28

    Nov

VBTX

Veritex

$27.04

-0.02 (-0.07%)

18:20
10/19/17
10/19
18:20
10/19/17
18:20
Hot Stocks
Veritex receives regulatory approval for Liberty Bancshares merger »

Veritex Holdings, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

BHP

BHP Billiton

$41.56

0.06 (0.14%)

18:03
10/19/17
10/19
18:03
10/19/17
18:03
Hot Stocks
BHP Billiton CEO sees challenges around geopolitical uncertainty remaining »

In annual shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRRX

Durect

$1.97

0.03 (1.55%)

17:59
10/19/17
10/19
17:59
10/19/17
17:59
Hot Stocks
Durect: Phase 3 clinical trial for POSIMIR did not meet primary endpoint »

Durect reported that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTNP

Titan Pharmaceuticals

$1.90

-0.1 (-5.00%)

17:49
10/19/17
10/19
17:49
10/19/17
17:49
Hot Stocks
Titan Pharmaceuticals presents non-clinical data from liothyronine implant »

Titan Pharmaceuticals is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSA

MSA Safety

$82.20

1.37 (1.69%)

17:46
10/19/17
10/19
17:46
10/19/17
17:46
Earnings
MSA Safety reports Q3 EPS 92c, consensus 80c »

Reports Q3 revenue $296M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

SKX

Skechers

$24.03

-1.06 (-4.22%)

, CAI

CAI International

$31.38

-0.05 (-0.16%)

17:41
10/19/17
10/19
17:41
10/19/17
17:41
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

SKX

Skechers

$24.03

-1.06 (-4.22%)

CAI

CAI International

$31.38

-0.05 (-0.16%)

PYPL

PayPal

$67.25

-0.01 (-0.01%)

MXIM

Maxim Integrated

$50.09

0.24 (0.48%)

IMDZ

Immune Design

$5.50

-1.05 (-16.03%)

NCR

NCR Corp.

$37.05

-0.26 (-0.70%)

TACO

Del Taco

$15.39

-0.01 (-0.06%)

ATHN

athenahealth

$116.41

-4.37 (-3.62%)

ISRG

Intuitive Surgical

$357.46

3.09 (0.87%)

ETFC

E-Trade

$43.69

-0.23 (-0.52%)

CELG

Celgene

$135.96

-1.21 (-0.88%)

PBMD

Prima BioMed

$2.36

-0.02 (-0.84%)

AAXN

Axon

$24.62

-0.37 (-1.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

  • 21

    Oct

  • 22

    Oct

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 08

    Nov

  • 29

    Nov

DGX

Quest Diagnostics

$93.23

1.18 (1.28%)

17:37
10/19/17
10/19
17:37
10/19/17
17:37
Hot Stocks
Quest Diagnostics acquires Cleveland HeartLab, terms not disclosed »

Advantage Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 06

    Nov

  • 30

    Nov

AAXN

Axon

$24.62

-0.37 (-1.48%)

17:34
10/19/17
10/19
17:34
10/19/17
17:34
Hot Stocks
Axon says now aware of comment letter over SEC's review of 10-K, 10-Q »

Axon Enterprise said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPMX

BioPharmX

17:29
10/19/17
10/19
17:29
10/19/17
17:29
Syndicate
Breaking Syndicate news story on BioPharmX »

BioPharmX files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBVX

MabVax Therapeutics

$0.74

0.0248 (3.47%)

17:29
10/19/17
10/19
17:29
10/19/17
17:29
Syndicate
Breaking Syndicate news story on MabVax Therapeutics »

MabVax Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBKC

Iberiabank

$80.15

0.05 (0.06%)

17:28
10/19/17
10/19
17:28
10/19/17
17:28
Earnings
Iberiabank reports Q3 non-GAAP EPS $1.00, consensus $1.16 »

Reports Q3 core revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 15

    Nov

  • 28

    Nov

DRRX

Durect

$1.97

0.03 (1.55%)

17:28
10/19/17
10/19
17:28
10/19/17
17:28
Hot Stocks
Breaking Hot Stocks news story on Durect »

Durect trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCP

Quality Care Properties

$16.26

0.07 (0.43%)

17:26
10/19/17
10/19
17:26
10/19/17
17:26
Hot Stocks
Quality Care Properties provides update on HCR ManorCare »

Quality Care Properties…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTR

Frontier Communications

$11.48

0.02 (0.17%)

, CHH

Choice Hotels

$68.45

0.25 (0.37%)

17:26
10/19/17
10/19
17:26
10/19/17
17:26
Hot Stocks
Frontier Communications named a Qualified Vendor with Choice Hotels Internationa »

Frontier Communications…

FTR

Frontier Communications

$11.48

0.02 (0.17%)

CHH

Choice Hotels

$68.45

0.25 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 06

    Nov

  • 08

    Nov

DRIO

DarioHealth

$1.98

-0.2 (-9.17%)

17:16
10/19/17
10/19
17:16
10/19/17
17:16
Syndicate
Breaking Syndicate news story on DarioHealth  »

DarioHealth files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CUBI

Customers Bancorp

$33.16

0.46 (1.41%)

17:11
10/19/17
10/19
17:11
10/19/17
17:11
Hot Stocks
Customers Bancorp to spin off BankMobile business »

Customers Bancorp plans…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 15

    Nov

MVC

MVC Capital

$10.40

0.08 (0.78%)

17:07
10/19/17
10/19
17:07
10/19/17
17:07
Hot Stocks
MVC Capital: Glass Lewis, Egan-Jones against proposal to cease new investments »

MVC Capital announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

CELG

Celgene

$135.96

-1.21 (-0.88%)

17:05
10/19/17
10/19
17:05
10/19/17
17:05
Hot Stocks
Breaking Hot Stocks news story on Celgene »

Celgene down 6.6% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 08

    Nov

NGD

New Gold

$3.57

0.03 (0.85%)

17:03
10/19/17
10/19
17:03
10/19/17
17:03
Hot Stocks
New Gold says Rainy River Mine achieves commercial production »

New Gold reported that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

COR

CoreSite Realty

$114.84

0.01 (0.01%)

17:02
10/19/17
10/19
17:02
10/19/17
17:02
Syndicate
Breaking Syndicate news story on CoreSite Realty »

CoreSite Realty files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 13

    Nov

SXT

Sensient

$78.26

-0.43 (-0.55%)

17:02
10/19/17
10/19
17:02
10/19/17
17:02
Earnings
Breaking Earnings news story on Sensient »

Sensient backs FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.